Integrated Cancer Repository for Cancer Research
iCaRe2
1 other identifier
observational
999,999
1 country
42
Brief Summary
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2013
Longer than P75 for all trials
42 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2013
CompletedFirst Submitted
Initial submission to the registry
December 2, 2013
CompletedFirst Posted
Study publicly available on registry
December 16, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2099
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2099
May 5, 2026
June 1, 2025
86.1 years
December 2, 2013
April 28, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Development and Implementation of a Web-based Cancer Collaborative Registry
This is a registry that will continue to accrue participants indefinitely.
86 years
Secondary Outcomes (1)
Procurement and Banking of Excess Biological Material for Future Analysis
86 years
Other Outcomes (1)
Collection and Banking of Blood, DNA, and Urine Samples for Future Studies
86 years
Eligibility Criteria
Any individual who meets the eligibility criteria will be invited to participate in iCaRe2.
You may qualify if:
- Diagnosis/history of cancer
- Risk for developing cancer or suspicious clinical findings
- No history of cancer (normal control registry)
- Able to provide informed consent
- years of age or older
- English or Spanish speaking individuals
You may not qualify if:
- Unable to provide informed consent because of cognitive impairment
- Non-English or non-Spanish speaking individuals
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (42)
Advent Health
Greenwood Village, Colorado, 80111, United States
Hartford HealthCare Cancer Institute at Manchester Medical Hospital
Manchester, Connecticut, 06040, United States
Florida Hospital Memorial Medical Center
Daytona Beach, Florida, 32117, United States
Florida Hospital DeLand
DeLand, Florida, 32720, United States
Florida Hospital FISH
Orange City, Florida, 32763, United States
Florida Hospital Flagler
Palm Coast, Florida, 32164, United States
Tallahassee Memorial Hospital
Tallahassee, Florida, 32308, United States
Rush-Copley Cancer Care Center
Aurora, Illinois, 60504, United States
Rush-Copley Healthcare Center
Yorkville, Illinois, 60560, United States
Parkview Research Center
Fort Wayne, Indiana, 46845, United States
Methodist Jennie Edmundson Hospital
Council Bluffs, Iowa, 51503, United States
Covenant Medical Center, Inc
Waterloo, Iowa, 50702, United States
Saint Luke's Cancer Instititute - South
Overland Park, Kansas, 66213, United States
Northwest Hospital
Randallstown, Maryland, 21133, United States
William E. Kahlert Regional Cancer Center
Westminster, Maryland, 21157, United States
Holyoke Medical Center
Holyoke, Massachusetts, 01040, United States
Riverwood Healthcare Center
Aitkin, Minnesota, 56431, United States
Essentia Health-St. Joseph's Medical Center
Brainerd, Minnesota, 56401, United States
Essentia Health - Duluth Clinic
Duluth, Minnesota, 55805, United States
St. Luke's Hospital of Duluth
Duluth, Minnesota, 55805, United States
Lake Region Healthcare
Fergus Falls, Minnesota, 56537, United States
Saint Luke's Cancer Institute, East
Kansas City, Missouri, 64086, United States
Saint Luke's Cancer Institute
Kansas City, Missouri, 64111, United States
Saint Luke's Cancer Institute, Kansas City North
Kansas City, Missouri, 64118, United States
Saint Luke's Cancer Institute, Liberty
Liberty, Missouri, 64068, United States
North Kansas City Hospital
North Kansas City, Missouri, 64116, United States
Heartland Regional Medical Center dba Mosaic Life Care
Saint Joseph, Missouri, 64507, United States
Bozeman Health Deaconess Hospital
Bozeman, Montana, 59715, United States
Mary Lanning Healthcare, Morrison Cancer Center
Hastings, Nebraska, 68901, United States
Faith Regional Health Services, Carson Cancer Center
Norfolk, Nebraska, 68701, United States
Great Plains Regional Medical Center
North Platte, Nebraska, 69101, United States
Methodist Estabrook Cancer Center
Omaha, Nebraska, 68114, United States
Nebraska Methodist Health System
Omaha, Nebraska, 68114, United States
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
C.R. Wood Cancer Center, Glens Falls Hospital
Glens Falls, New York, 12801, United States
Faxton St. Luke's Healthcare, Mohawk Valley
Utica, New York, 13501, United States
Cape Fear Valley Health System
Fayetteville, North Carolina, 28304, United States
Essentia Health
Fargo, North Dakota, 58103, United States
Trinity Hospital Cancer Care Center
Minot, North Dakota, 58701, United States
Aultman Alliance Community Hospital
Alliance, Ohio, 44601, United States
Aultman Hospital
Canton, Ohio, 44710, United States
Bellin Memorial Hospital
Green Bay, Wisconsin, 54305, United States
Related Links
Biospecimen
Blood: Optional Donation. At enrollment and other time points during routine care visits, typically before or after treatment changes. Approximate amounts are 2 tablespoons and total annual amount will not exceed 20 tablespoons. Urine: Optional Donation. At enrollment and follow up appointments, if on active study. Tissue: Portion of leftover tissue collected and saved from surgery/biopsy, including,but not limited to tumor tissue and/or metastatic cancer tissue and/or paraffin embedded tissue prospectively or retrospectively collected. Questionnaire: Baseline and follow up.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Kurt Fisher, MD, PhD
University of Nebraska
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 80 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 2, 2013
First Posted
December 16, 2013
Study Start
November 1, 2013
Primary Completion (Estimated)
December 1, 2099
Study Completion (Estimated)
December 1, 2099
Last Updated
May 5, 2026
Record last verified: 2025-06
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, ICF
- Time Frame
- as long as the registry is open
- Access Criteria
- Institutional Review Board approval to analyze data for separate study
All data and/or specimen request have to be made to the Principal Investigator of the center and follow the Human Subject Protection guidelines and policy.